News

circle_logo2

Graybug and CalciMedica Enter into Definitive Merger Agreement

Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases Combined company is expected to …

CalciMedica Announces Publication of Preclinical Data in EMBO Molecular Medicine Supporting the Development of CRAC Channel Inhibitors for Inflammatory Bowel Disease (IBD)

– Study provides further validation of the potentially broad utility for CRAC channel inhibitors in inflammatory diseases– Data show that inhibiting store-operated Ca2+ entry (SOCE) …

CalciMedica Announces Publication of Results from CARDEA COVID-19 Study in Critical Care

– Results further support therapeutic potential of Auxora in respiratory diseases and other inflammatory diseases – LA JOLLA, Calif., April 14, 2022 – CalciMedica Inc. (CalciMedica …

CalciMedica Announces Publication of Peer-Reviewed Paper in The Journal of Physiology

Study Supports Development of CRAC Channel Inhibitors for Acute Pancreatitis Study indicates that Orai1 inhibition prevents impaired ductal cell function in acute pancreatitis (AP) Data …

CalciMedica Initiates CARDEA-Plus: A Clinical Trial of Auxora™ in Patients with Critical COVID-19 Pneumonia

CARDEA-Plus is designed to evaluate dosing, safety and efficacy of Auxora in combination with both tocilizumab and corticosteroids LA JOLLA, Calif., January 20, 2022 – CalciMedica …

Scroll to Top